Clinical trials: Head &Amp; Neck Squamous Cell Carcinoma
Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
- Trial name
- CAPT-HN (NCT07062354)
- Testing
- Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- SWOG Cancer Research Network
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Head &Amp;Amp; Neck Squamous Cell Carcinoma
The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck
en-label, proof-of-concept study designed to evaluate the feasibility, safety, and acceptability of a prophylactic fish oil-enriched nutritional supplement (Fresubin Supportan) in patients with head and neck cancer (HNC)…
- Trial name
- FORCE (NCT07180576)
- Testing
- Nutrition counseling, Fresubin Supportan
- Volunteers
- 15 people
- Sponsor
- Anna Arthur, PhD
Head &Amp; Neck Squamous Cell Carcinoma
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)
This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.
- Trial name
- NeoTempo (NCT07147426)
- Testing
- Tislelizumab Combined With Chemotherapy for 4 cycles, Tislelizumab Combined With Chemotherapy for 2 cycles
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Radiation-Induced Oral Mucositis, Head &Amp; Neck Cancer
Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy.
- Conditions
- Radiation-Induced Oral Mucositis, Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
- Trial name
- RICE-MUC (NCT07242859)
- Testing
- rice bran
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Christina Milad Lobos
Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Head &Amp;Amp; Neck Squamous Cell Carcinoma
Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
Delays between surgery and the initiation of post-operative radiotherapy (S-PORT) in head and neck cancer (HNC) patients are prevalent and associated with worse oncologic outcomes.
- Conditions
- Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Head &Amp;Amp; Neck Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
- Trial name
- PRONTO-HN (NCT07180901)
- Testing
- Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)
- Where
- Canada
- Volunteers
- 85 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
This is a Phase I, open-label, dual-cohort clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of intratumoral injection of recombinant human endostatin adenovirus in combination with a PD-1…
- Trial name
- NCT07154108
- Testing
- recombinant human endostatin adenovirus, PD-1 Inhibitor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University